Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Synthetic Phenolic Antioxidants and Their Metabolites in Follicular Fluid and Association with Diminished Ovarian Reserve: A Case–Control Study

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Diminished/decreased ovarian reserve (DOR) is a disorder of ovarian function, which severely affects women’s reproductive health. Accumulating evidence has found that adverse environmental factors can affect ovarian function. However, whether synthetic phenolic antioxidants (SPAs) exposure is associated with DOR is still unknown.

          Objectives:

          We explored whether concentrations of SPAs and their metabolites are associated with DOR.

          Methods:

          A case–control study was conducted from January 2019 to January 2020 in China. One hundred eighty-one women 20–44 years of age, with (case group, n = 63 ) and without DOR (control group, n = 118 ) were included in our study. The follicular fluid concentrations of typical SPAs and their metabolites were measured, including butylated hydroxyanisole (BHA), tert-butylhydroquinone (TBHQ), butylated hydroxytoluene (BHT), and five BHT metabolites [3,5-di- tert-butyl-4-hydroxy-benzylalcohol (BHT-OH), 3,5-di- tert-butyl-4-hydroxybenzaldehyde (BHT-CHO), 3,5-di- tert-butyl-4-hydroxybenzoic acid (BHT-COOH), 2,6-di- tert-butyl-1,4-benzoquinone (BHT-Q), and 2,6-di- tert-butyl-4-hydroxy-4-methylcyclohexa-2,5-dien-1-one (BHT-quinol)]. Information about serum basal concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and anti-Müllerian hormone (AMH) and the basal antral follicle count (AFC) was collected.

          Results:

          The measured frequencies of BHA, TBHQ, BHT, BHT-OH, BHT-CHO, BHT-COOH, BHT-Q, and BHT-quinol in follicular fluid were 1.7%, 2.2%, 40.3%, 46.4%, 57.5%, 100%, 64.6%, and 49.2%, respectively. The concentrations of BHT-CHO ( 0.49  ng / mL vs. 0.12  ng / mL , p = 0.041 ), BHT-COOH ( 0.45  ng / mL vs. 0.28  ng / mL , p < 0.001 ), BHT-Q ( 0.70  ng / mL vs. 0.13  ng / mL , p < 0.001 ), and the sum of five BHT metabolites ( Σ 5 metabolites ; 1.79  ng / mL vs. 1.0  ng / mL , p < 0.001 ) in the case group were significantly higher than those in the control group. The risk of DOR was further analyzed according to the tertiles of chemical concentration. Compared with the low levels of BHT metabolites, the adjusted odds ratios (ORs) for DOR were significantly increased in the high levels of BHT-CHO [ OR = 3.19 , 95% confidence interval (CI): 1.22, 8.31, p = 0.018 ], BHT-COOH [ OR = 4.73 (95% CI: 1.63, 13.71), p = 0.004 ], and BHT-Q [ OR = 4.48 (95% CI: 1.69, 11.86), p = 0.003 ] after adjusting for age, body mass index, education, infertility type, triglycerides, and total cholesterol. Moreover, compared with the low level of Σ 5 metabolites , increased adjusted ORs for DOR were found both in the middle level [ OR = 4.11 (95% CI: 1.44, 11.75), p = 0.008 ] and high level [ OR = 5.51 (95% CI: 1.81, 16.77), p = 0.003 ], showing an obvious dose–response relationship ( p Trend = 0.003 ).

          Conclusion:

          In this study, we report the measured frequency and concentrations of BHA, TBHQ, BHT, and their metabolites in follicular fluid. Moreover, we found the concentrations of BHT metabolites, especially BHT-CHO, BHT-COOH, and BHT-Q, are positively associated with the increased risk of DOR. https://doi.org/10.1289/EHP11309

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          The International Glossary on Infertility and Fertility Care, 2017.

          Can a consensus and evidence-driven set of terms and definitions be generated to be used globally in order to ensure consistency when reporting on infertility issues and fertility care interventions, as well as to harmonize communication among the medical and scientific communities, policy-makers, and lay public including individuals and couples experiencing fertility problems?
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health.

            Bidirectional somatic cell-oocyte signaling is essential to create a changing intrafollicular microenvironment that controls primordial follicle growth into a cohort of growing follicles, from which one antral follicle is selected to ovulate a healthy oocyte. Such intercellular communications allow the oocyte to determine its own fate by influencing the intrafollicular microenvironment, which in turn provides the necessary cellular functions for oocyte developmental competence, which is defined as the ability of the oocyte to complete meiosis and undergo fertilization, embryogenesis, and term development. These coordinated somatic cell-oocyte interactions attempt to balance cellular metabolism with energy requirements during folliculogenesis, including changing energy utilization during meiotic resumption. If these cellular mechanisms are perturbed by metabolic disease and/or maternal aging, molecular damage of the oocyte can alter macromolecules, induce mitochondrial mutations, and reduce adenosine triphosphate production, all of which can harm the oocyte. Recent technologies are now exploring transcriptional, translational, and post-translational events within the human follicle with the goal of identifying biomarkers that reliably predict oocyte quality in the clinical setting.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ovarian reserve testing: a user's guide.

              Ovarian reserve is a complex clinical phenomenon influenced by age, genetics, and environmental variables. Although it is challenging to predict the rate of an individual's ovarian reserve decline, clinicians are often asked for advice about fertility potential and/or recommendations regarding the pursuit of fertility treatment options. The purpose of this review is to summarize the state-of-the-art of ovarian reserve testing, providing a guide for the obstetrician/gynecologist generalist and reproductive endocrinologist. The ideal ovarian reserve test should be convenient, be reproducible, display little if any intracycle and intercycle variability, and demonstrate high specificity to minimize the risk of wrongly diagnosing women as having diminished ovarian reserve and accurately identify those at greatest risk of developing ovarian hyperstimulation prior to fertility treatment. Evaluation of ovarian reserve can help to identify patients who will have poor response or hyperresponse to ovarian stimulation for assisted reproductive technology. Ovarian reserve testing should allow individualization of treatment protocols to achieve optimal response while minimizing safety risks. Ovarian reserve testing may inform patients regarding their reproductive lifespan and menopausal timing as well as aid in the counselling and selection of treatment for female cancer patients of reproductive age who receive gonadotoxic therapy. In addition, it may aid in establishing the diagnosis of polycystic ovary syndrome and provide insight into its severity. While there is currently no perfect ovarian reserve test, both antral follicular count and antimüllerian hormone have good predictive value and are superior to day-3 follicle-stimulating hormone. The convenience of untimed sampling, age-specific values, availability of an automated platform, and potential standardization of antimüllerian hormone assay make this test the preferred biomarker for the evaluation of ovarian reserve in women.
                Bookmark

                Author and article information

                Journal
                Environ Health Perspect
                Environ Health Perspect
                EHP
                Environmental Health Perspectives
                Environmental Health Perspectives
                0091-6765
                1552-9924
                2 June 2023
                June 2023
                : 131
                : 6
                : 067005
                Affiliations
                [ 1 ]Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital , Beijing, China
                [ 2 ]National Clinical Research Center for Obstetrics and Gynecology , Beijing, China
                [ 3 ]Key Laboratory of Assisted Reproduction, Ministry of Education , Beijing, China
                [ 4 ]Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology , Beijing, China
                [ 5 ]Department of Child, Adolescent Health and Maternal Care, School of Public Health, Capital Medical University , Beijing, China
                [ 6 ]Research Units of Comprehensive Diagnosis and Treatment of Oocyte Maturation Arrest, Chinese Academy of Medical Sciences , Beijing, China
                [ 7 ]School of Environment, Jinan University , Guangzhou, China
                [ 8 ]Guangdong Key Laboratory of Environmental Pollution and Health, Jinan University , Guangzhou, China
                [ 9 ]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinery Studies, Peking University , Beijing, China
                Author notes
                Address corresponding to Yue Zhao, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, No. 49 North Huayuan Rd., Haidian District, Beijing 100191, China. Telephone: 86-010-82265080. Email: zhaoyue0630@ 123456163.com . And, Jie Qiao, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, No. 49 North Huayuan Rd., Haidian District, Beijing 100191, China. Telephone: 86-010-82265080. Email: jie.qiao@ 123456263.net .
                Article
                EHP11309
                10.1289/EHP11309
                10237312
                37267061
                c76d9598-0d24-4c57-8416-585dd097c996

                EHP is an open-access journal published with support from the National Institute of Environmental Health Sciences, National Institutes of Health. All content is public domain unless otherwise noted.

                History
                : 25 March 2022
                : 22 April 2023
                : 09 May 2023
                Categories
                Research

                Public health
                Public health

                Comments

                Comment on this article